Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chengda Pharmaceuticals CoSZSE:301201 +2.44%78 5-Year Yield-on-Cost % is 0.74 as of Aug. 02, 2026, which is 19% below its 10-year median of 0.91. GuruFocus rates SZSE:301201 with a GF Score™ of 78/100 and a GF Value™ of ¥30.45 (Fairly Valued). The stock has 4 warning signs investors should review. Among 513 Drug Manufacturers companies, Chengda Pharmaceuticals Co ranks worse than 76.41% on this metric.
The historical rank and industry rank for Chengda Pharmaceuticals Co's 5-Year Yield-on-Cost % or its related term are showing as below:
SZSE:301201'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.33 Med: 0.91 Max: 1.75
Current: 0.74
During the past 12 years, Chengda Pharmaceuticals Co's highest Yield on Cost was 1.75. The lowest was 0.33. And the median was 0.91.
SZSE:301201's 5-Year Yield-on-Cost % is ranked worse than 76.41% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.32
vs SZSE:301201: 0.74
Chengda Pharmaceuticals Co (SZSE:301201) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Chengda Pharmaceuticals Co 5-Year Yield-on-Cost % Related Terms
SZSE:301201 vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Chengda Pharmaceuticals Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengda Pharmaceuticals Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chengda Pharmaceuticals Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Chengda Pharmaceuticals Co's 5-Year Yield-on-Cost % falls into.
Chengda Pharmaceuticals Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Chengda Pharmaceuticals Co (SZSE:301201) has a 5-Year Yield-on-Cost % of 0.74 as of Aug. 02, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Chengda Pharmaceuticals Co and its competitors. This is 19% below median its historical median of 0.91. Over the past decade, Chengda Pharmaceuticals Co's 5-Year Yield-on-Cost % has ranged from 0.33 to 1.75. According to the industry distribution chart, Chengda Pharmaceuticals Co ranks #392 out of 513 companies in the Drug Manufacturers industry, placing it in the top 76.4%.
Is Chengda Pharmaceuticals Co's 5-Year Yield-on-Cost % too high?
Chengda Pharmaceuticals Co's current 5-Year Yield-on-Cost % of 0.74 is 19% below median its 10-year median of 0.91. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 1.75. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.32. Chengda Pharmaceuticals Co's value of 0.74 is 68.1% below this industry median. Based on the distribution chart, Chengda Pharmaceuticals Co ranks #392 out of 513 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Chengda Pharmaceuticals Co has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chengda Pharmaceuticals Co's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Chengda Pharmaceuticals Co ranks #392 out of 513 companies for 5-Year Yield-on-Cost %. This places Chengda Pharmaceuticals Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.32. Chengda Pharmaceuticals Co's value of 0.74 is 68.1% below this benchmark. Historically, Chengda Pharmaceuticals Co's own 5-Year Yield-on-Cost % has ranged from 0.33 to 1.75 over the past decade. While the company's 10-year median is 0.91 vs. the industry median of 2.32, Chengda Pharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.32, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chengda Pharmaceuticals Co's current 5-Year Yield-on-Cost % of 0.74 is 68.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Chengda Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chengda Pharmaceuticals Co's current 5-Year Yield-on-Cost % is 0.74, which is 19% below median its own 10-year median of 0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengda Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co (SZSE:301201) is currently considered Fairly Valued. The stock's GF Value™ is ¥30.45, compared to a current price of ¥27.74 — trading 8.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.74, which is 19% below median its 10-year median of 0.91 and 68.1% below the Drug Manufacturers industry median of 2.32. Chengda Pharmaceuticals Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Chengda Pharmaceuticals Co (SZSE:301201), the current 5-Year Yield-on-Cost % is 0.74 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengda Pharmaceuticals Co (SZSE:301201) Overvalued in 2026?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥27.74 is trading 8.9% below its estimated GF Value™ of ¥30.45.
GuruFocus considers Chengda Pharmaceuticals Co to be Fairly Valued.
Key valuation signals for SZSE:301201:
5-Year Yield-on-Cost %: 0.74 (19% below median its 10-year median of 0.91)
GF Value™: ¥30.45 vs. price of ¥27.74 (8.9% below fair value)
Industry Position: 68.1% below the Drug Manufacturers median (#392 of 513)
No single metric tells the full story. See the SZSE:301201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengda Pharmaceuticals Co Ltd is engaged in the research and development, production and sales of L-carnitine series products. The company mainly produces raw materials, food additives, feed additives, antibiotics, anti-cancer, anti-virus and other series of pharmaceutical intermediates. The products are sold to more than 30 countries and regions.
78GF Score
Get the complete analysis for SZSE:301201
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301201 has been successfully added to your 
